Replicor is a privately held biopharmaceutical company located in Montreal, Canada. Our novel nucleic acid polymer (NAP) technology has the unique ability to eliminate the viral surface antigen protein in patients with HBV and HDV infection, a key step in achieving functional cure in these patients. NAP-based combination therapy has produced the most advanced animal and human clinical data in the development of the cure for HBV and HDV infection. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection.